• Araceli López-Facundo, Cecilia Rodríguez-Castillejos, Yulia Romero, Juan Gay, and Diddier Prada.
• Instituto de Seguridad Social del Estado de México y Municipios, Hospital Materno Infantil, Estado de México. México.
• Gac Med Mex. 2019 Jan 1; 155 (4): 369-376.

IntroductionFew studies have assessed the economic impact of inhibitors in hemophilia A in Mexico, especially in the pediatric population.ObjectiveTo determine the economic impact entailed by the development of inhibitors in pediatric patients with hemophilia A.MethodPatients with hemophilia A under the care of a pediatric hematology department between December 2015 and November 2017 were retrospectively assessed. Direct and indirect costs were determined based on the presence or absence of inhibitors.ResultsThe cost analysis of the study population (n = 24) showed that diagnosis, follow-up, prophylaxis, treatment and hospitalization of these patients had an annual cost of $ 6 883 187.4 per patient, out of which more than 95 % depended on the use of hemostatic factors. Annual cost per patient in the group with inhibitors was $ 5 548 765.0 in comparison with $ 1 334 422.4 in the group without inhibitors, 4.2 times higher.ConclusionsThis is the first national study to show that the presence of inhibitors in pediatric patients with hemophilia A increases the cost of the disease more than four times.Copyright: © 2019 Permanyer.

24 keywords...

hide…